Biologic agents have become a core component of therapeutic strategies for many
inflammatory rheumatic diseases. However, perhaps reflecting the specificity and generally …

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …

Objective To develop EULAR points-to-consider for therapeutic drug monitoring (TDM) of
biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs) …

The objectives of this review were to collect and summarise evidence on therapeutic drug
monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal …

Genome sequencing (GS) is increasingly being translated into clinical practice and is a
technology characterized by a complex multi-step workflow. Funding decisions for GS would …

Background Economic evaluations have suggested that risk-stratified breast cancer
screening may be cost-effective but have used assumptions to estimate the cost of risk …

BACKGROUND Rheumatoid arthritis is a chronic autoimmune disease that primarily causes
inflammation, pain and stiffness in the joints. People with severe disease may be treated …

Introducing precision medicine strategies into routine practice will require robust economic
evidence. Decision-makers need to understand the value of a precision medicine strategy …

Background Rheumatoid arthritis (RA) is a long term condition that requires early treatment
to control symptoms and improve long-term outcomes. Lack of response to RA treatments is …

Objective Therapeutic drug monitoring (TDM) of tumour necrosis factor-α inhibitors (TNFi),
by measuring drug levels and/or anti-drug antibodies, is being considered by various …